Keenova Therapeutics plc
DelistedCIK 1567892fmd_0Y8JMDY6WWX6CP3YWSNTYVTZV4Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Sep 25, 2010 to Sep 30, 2026, 62 periods
| Line item | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | 3,222 | 3,216 | 3,163 | 2,213 | 2,209 | 1,083 | 1,431 |
| Cost of revenue | 766 | 1,300 | 1,526 | 1,564 | 1,744 | 1,741 | 1,544 | 1,317 | 544 | 788 |
| Gross profit | 885 | 1,623 | 1,855 | 1,658 | 1,471 | 1,421 | 669 | 892 | 539 | 643 |
| Research and development | 141 | 203 | 262 | 277 | 361 | 349 | 291 | 205 | 89 | 91 |
| Selling, general and administrative | 611 | 1,024 | 925 | 850 | 834 | 831 | 884 | 581 | 462 | 761 |
| Operating income | 43 | 354 | 617 | 493 | (3,721) | (1,822) | (652) | (203) | (66) | (348) |
| Interest expense | 83 | 256 | 385 | 369 | 370 | 309 | 261 | 223 | 228 | 169 |
| Other non-operating income (expense) | 3 | 8 | (1) | (75) | 22 | 64 | 7 | 22 | (7) | 6 |
| Income before taxes | (35) | 107 | 233 | 62 | (4,052) | (1,592) | (961) | (830) | 458 | (481) |
| Income tax expense | (13) | (129) | (256) | (1,710) | (430) | (584) | 9 | (106) | 113 | (24) |
| Net income from continuing operations | (22) | 237 | 489 | 1,771 | (3,622) | (1,007) | (970) | (724) | 344 | (458) |
| Net income | (319) | 325 | 644 | 2,134 | (3,607) | (997) | (945) | (717) | 478 | (490) |
| Net income to common shareholders | (319) | 322 | 644 | 2,134 | (3,607) | – | – | – | – | – |